BioMarin to acquire Alesta Therapeutics

BioMarin Pharmaceutical (BMRN) rose 6.9% after Q2 results. Myriad Genetics (MYGN) fell 41.8% with revenue down 10.5% YoY, missing estimates. Halozyme Therapeutics (HALO) gained 25% with revenue up 47.7% YoY, beating expectations. Vertex Pharmaceuticals (VRTX) increased 16.3% with revenue up 12.5% YoY, topping forecasts.

BioMarin (BMRN) agreed to acquire Alesta Therapeutics for $275M upfront, with up to $215M in milestones. The deal expands BioMarin's rare disease pipeline, adding ALE1, a potential oral treatment for hypophosphatasia. BioMarin shares rose 4.7% premarket. The acquisition will be funded with existing cash and is expected to close this quarter.

BioMarin Pharmaceutical (BMRN) acquired Alesta Therapeutics for $275M upfront, gaining rights to ALE1, an oral treatment for hypophosphatasia (HPP). ALE1 is in early trials, with BioMarin potentially paying $215M more if milestones are met. The deal aligns with BioMarin's focus on rare skeletal diseases and follows its $4.8B acquisition of Amicus Therapeutics.

BioMarin Pharmaceutical (BMRN) rose 3.5% after acquiring Alesta Therapeutics for $275M upfront, with up to $215M in milestones. Analysts reacted positively, with Barclays and Piper Sandler raising price targets. The stock closed at $69.33, near its 52-week high.

BioMarin Pharmaceutical agreed to acquire Alesta Therapeutics for $275 million upfront, with up to $215 million in milestone payments. The deal focuses on ALE1, an oral treatment for hypophosphatasia (HPP), currently in Phase 1/2a trials. BioMarin plans to fund the acquisition with cash and expects it to close in Q3 2026, subject to conditions.

BioMarin Pharmaceutical (BMRN) agreed to buy Alesta Therapeutics for $275 million upfront plus $215 million in development and regulatory milestones, to gain rights to clinical-stage ALE1 for hypophosphatasia. ALE1 is in Phase 1/2a. Deal is expected to close this quarter; it may modestly dilute 2026 results and will be funded with cash on hand.